Coherus BioSciences Inc (NAS:CHRS)
$ 1.78 0.02 (1.14%) Market Cap: 204.21 Mil Enterprise Value: 423.31 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 11:35PM GMT
Release Date Price: $17.19 (+1.90%)
Ashwani Verma
BofA Merrill Lynch, Research Division - Research Analyst

Good afternoon, everyone. So our next company here that we have on stage is Coherus BioSciences. It's a pure-play biosimilar company and has just launched its first product. So -- and my name is Ashwani Verma. I work for the Bank of America U.S. Major and Specialty Pharma team. And with me is Jean Viret, from Coherus, who's the CFO. So good afternoon to you and welcome onboard.

Jean;FrÃ;dÃ;ric Viret
Coherus BioSciences, Inc. - CFO

©© -

Thank you, Ashwani.

Questions & Answers

Ashwani Verma;
BofA Merrill Lynch, Research Division - Research Analyst

So just wanted to get started on some of the questions. I mean, give us a sense of, say, you recently launched your first product and give us a sense of where the company is in its journey towards commercialization. And what are some of things -- the top 3 or 4 things that the investor should focus on right now about the story?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot